A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma

This is a phase 1/2 multicenter, open-label, first-in-human study of IBI3003. It includes a phase 1 dose escalation and expansion section to identify maximum tolerated dose(MTD)/recommended Phase 2 Dose(RP2D) of IBI3003, plans to enroll 54\~360 subjects, and a phase 2 stage to explore efficacy, safety and tolerability of IBI3003 at RP2D in multiple myeloma

Trial Details

NCT ID
NCT07336472
Phase
PHASE1 / PHASE2
Sponsor
Fortvita Biologics (USA)Inc.
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • IBI3003
Locations (sample)
  • Scottsdale, Arizona, United States|33.50921,-111.89903
  • Duarte, California, United States|34.13945,-117.97729
  • Irvine, California, United States|33.66946,-117.82311
  • Atlanta, Georgia, United States|33.749,-84.38798
  • New York, New York, United States|40.71427,-74.00597

Key Eligibility Criteria

  • Participants in Parts 1 \& 2 must satisfy all of the following criteria to be enrolled in the study:
  • Age ≥18 years.
  • Documented initial diagnosis of multiple myeloma according to IMWG diagnostic criteria.
  • Multiple myeloma is defined as clonal bone marrow plasma cells ≥10% or biopsy-proven bony or extramedullary plasmacytoma, and any one or more of th…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →